10,609 results
Search Results
102. Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience
103. PROTAC-mediated CDK degradation differentially impacts cancer cell cycles due to heterogeneity in kinase dependencies
104. Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers
105. Progress in Clinical and Biological Research: vol. 25. Recent Advances in Clinical Oncology.
106. COVID-19 and the multidisciplinary care of patients with lung cancer: an evidence-based review and commentary.
107. Metformin use and lung cancer survival: a population-based study in Norway
108. Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site
109. A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma
110. Deletion of the deISGylating enzyme USP18 enhances tumour cell antigenicity and radiosensitivity
111. The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients
112. Understanding the impact of sex and stage differences on melanoma cancer patient survival: a SEER-based study
113. Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer
114. Recording the gross outlines of breast tumours. A pathological assessment of the accuracy of radiographs of breast cancers.
115. Accumulation of Phosphoethanolamine in the Livers of Rats Injected with Hepatocarcinogens.
116. Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models.
117. The effect of time before diagnosis and treatment on colorectal cancer outcomes: systematic review and dose–response meta-analysis.
118. What sort of follow-up services would Australian breast cancer survivors prefer if we could no longer offer long-term specialist-based care? A discrete choice experiment.
119. Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations
120. Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials
121. Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
122. Central nervous system miliary metastasis in breast cancer: a case series analysis and proposed identification criteria of a rare metastasis subtype
123. Early treatment-related neutropenia predicts response to palbociclib
124. WD repeat-containing protein 1 maintains β-Catenin activity to promote pancreatic cancer aggressiveness
125. Cytochrome P450 1B1 polymorphism drives cancer cell stemness and patient outcome in head-and-neck carcinoma
126. Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer
127. First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor
128. Impact on survival of modelling increased surgical resection rates in patients with non-small-cell lung cancer and cardiovascular comorbidities: a VICORI study
129. Omental adipocytes promote peritoneal metastasis of gastric cancer through the CXCL2–VEGFA axis
130. miR-622 is a novel potential biomarker of breast carcinoma and impairs motility of breast cancer cells through targeting NUAK1 kinase
131. Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design
132. Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC
133. Bimodal magnetic resonance and optical imaging of extracellular matrix remodelling by orthotopic ovarian tumours
134. Exogenous hormone use, reproductive factors and risk of intrahepatic cholangiocarcinoma among women: results from cohort studies in the Liver Cancer Pooling Project and the UK Biobank
135. Enrichment of the tumour immune microenvironment in patients with desmoplastic colorectal liver metastasis
136. Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines
137. Stearoyl-CoA-desaturase-1 regulates gastric cancer stem-like properties and promotes tumour metastasis via Hippo/YAP pathway
138. The association between unexpected weight loss and cancer diagnosis in primary care: a matched cohort analysis of 65,000 presentations
139. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
140. Real-world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening
141. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
142. Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+tumour-infiltrating lymphocytes in oral squamous cell carcinoma
143. Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review
144. Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers
145. A novel stratification framework for predicting outcome in patients with prostate cancer
146. Young adulthood body mass index, adult weight gain and breast cancer risk: the PROCAS Study (United Kingdom)
147. miR-27a is a master regulator of metabolic reprogramming and chemoresistance in colorectal cancer
148. Non-inferiority randomised phase 3 trial comparing two radiation schedules (single vs. five fractions) in malignant spinal cord compression
149. Case–control study of paternal occupational exposures and childhood bone tumours and soft-tissue sarcomas in Great Britain, 1962–2010
150. Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.